Natasha E. Daughtrey

Natasha E. Daughtrey is a highly experienced partner in Goodwin Procter's Intellectual Property Litigation practice and a key member of the firm's Life Sciences Disputes group. Her practice primarily focuses on intellectual property litigation and strategic counseling, specializing in patents, trade secrets, and trademarks. She possesses technical expertise spanning a wide array of technologies, including pharmaceuticals, medical devices, software, electrical transmission lines, and cosmetics. Daughtrey is particularly noted for her work in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) litigation, reflecting a strong focus on the life sciences sector. She also serves as co-editor-in-chief of Goodwin's "Big Molecule Watch" blog, a resource dedicated to biologics, biosimilars, and BPCIA matters.

Daughtrey demonstrates versatility in her side preference, representing both innovator drug companies and biosimilar developers in complex patent disputes. While the tracked case data shows her on the plaintiff side for a biosimilar developer, Alvotech v. Regeneron Pharmaceuticals, Inc., her broader practice includes representing innovator companies, software developers, and individuals in patent infringement actions. She provides counsel to clients on both offensive and defensive IP strategies, including pre-litigation readiness for life sciences startups.

Since joining Goodwin Procter in 2011, where she previously served as a summer associate in 2009, Daughtrey has ascended to partner status. Her notable case experience includes serving as trial counsel for Teva in a patent infringement litigation against Eli Lilly and Company, which resulted in a jury verdict for Teva and over $170 million in damages, a case currently on appeal. She also represented biosimilar developers in BPCIA litigation that led to a favorable settlement, enabling the launch of the first rituximab biosimilar in the U.S.. Daughtrey's expertise is recognized by her inclusion as a Recommended Lawyer for Patent Litigation: Full Coverage by The Legal 500 US in 2024 and as a top ANDA litigator by Patexia in 2020.

Her experience extends to proceedings before the United States Patent and Trademark Office, including inter partes reviews (IPRs). Daughtrey is admitted to the California Bar, holding an active license (No. 319975). She holds an undergraduate double major in biology and political science and was a member of the San Diego Law Review during law school.